Form 8-K

8-K — DYADIC INTERNATIONAL INC

Accession: 0001493152-26-037257

Filed: 2026-08-12

Period: 2026-08-12

CIK: 0001213809

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

GRAPHIC (logo_001.jpg)

GRAPHIC (ex99-1_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001213809

2026-08-12

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the

Securities

Exchange Act of 1934

Date

of Report (date of earliest event reported): August 12, 2026

Dyadic

International, Inc.

(Exact

name of registrant as specified in its charter)

Delaware

001-32513

45-0486747

(State

or other jurisdiction of

incorporation

or organization)

(Commission

File

Number)

(I.R.S.

Employer

Identification

Number)

1044

North U.S. Highway One, Suite 201

Jupiter,

FL 33477

(Address

of principal executive offices and zip code)

(561)

743-8333

(Registrant’s

telephone number, including area code)

N/A

(Former

Name or Former Address, if Changed Since Last Report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

Stock, par value $0.001 per share

DYAI

The

Nasdaq Stock Market LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)

or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

2.02. Results of Operations and Financial Condition.

August 12, 2026, Dyadic International, Inc. (“Dyadic”) issued a press release announcing its results for the quarter ended

June 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein

by reference.

The

information in this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is furnished and shall not be deemed

“filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or

otherwise subject to the liabilities of such section. Such information shall not be incorporated by reference in any filing under the

Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item

9.01. Financial Statements and Exhibits.

(d)

Exhibits:

Exhibit

Number

Description

99.1

Press release issued by Dyadic International, Inc., dated August 12, 2026.

104

Cover

Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

DYADIC

INTERNATIONAL, INC.

Date:

August 12, 2026

By:

/s/

Mark A Emalfarb

Mark

A. Emalfarb

Chief

Executive Officer

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

DYADIC

ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS

ACCELERATING

COMMERCIALIZATION MOMENTUM ACROSS KEY BUSINESS AREAS

Dyadic to host earnings

call on August 12 at 5:00 pm ET

JUPITER,

FL — August 12, 2026 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”,

or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered,

animal-free proteins and enzymes for diverse commercial applications, today reported its financial results for the second quarter

ended June 30, 2026, highlighting significant progress in product commercialization, strategic partnerships, and C1 biomanufacturing

platform expansion.

“Our strong second-quarter performance

underscores Dyadic’s ongoing transformation into a commercial-stage biotechnology leader, “said

Joe Hazelton, President and COO. “We are driving commercial launches and sales of recombinant proteins, securing

recurring revenue through strategic partners, distribution and optimizing manufacturing yields across life sciences,

food and nutrition, and bioindustrial markets. Simultaneously, leading global health, government, academic and industry collaborations

continue to validate the speed, productivity, scalability and potential commercial viability of our proprietary

C1 expression system, while advancing C1-produced antibodies, vaccine antigens and other biologics toward broader preclinical evaluation

and potential future clinical and commercial adoption.”

Recent

Company Developments

●

Commercial

Sales & Product Shipments: Advanced the recombinant protein portfolio through Q2 product shipments directly and through distribution

partners. Subsequent to quarter-end, Dyadic completed shipments of six distinct recombinant protein products and generated initial

pilot sales of recombinant transferrin and growth factors for cultivated-meat applications.

●

OEM

Distribution Progress: Initiated Q2 shipments to IBT Bioservices under Dyadic’s OEM distribution agreement, with additional

shipments completed after quarter-end, supporting product evaluation, qualification and commercialization across IBT’s global

life-science customer network.

●

Proliant

Health & Biologicals: Proliant has begun commercialization of Albufree™ DX recombinant human albumin for life

science and diagnostic applications and announced plans to expand the Albufree™ portfolio with Albufree™ TX for cell

culture and Albufree™ CGT for cell and gene therapy applications, positioning Dyadic for future royalties.

●

Fermbox

Bio: Scaled commercialization and initial orders for recombinant DNase I (RNase-free) and recombinant human transferrin.

●

Inzymes:

Confirmed initial commercial sales of non-animal bovine chymosin, with a second product in development that could trigger milestone payments

and royalties.

●

Cell

Culture & Life-Science Products: Continued advancing animal-free recombinant proteins for cell-culture and related applications.

Pilot-scale process improvements increased recombinant human transferrin productivity by approximately 80%, further supporting

the potential for competitive manufacturing economics as Dyadic advances transferrin, albumin, growth factors and other recombinant

animal-free proteins toward broader commercial use.

●

Food

& Nutrition Pipeline Expansion: Initiated scale-up activities with BRIG BIO for recombinant bovine alpha-lactalbumin under

a funded development agreement. Subsequent to quarter-end, Dyadic expanded its precision-fermented dairy protein portfolio through

an additional development and commercialization agreement, broadening potential opportunities to generate future product, licensing

and royalty revenues.

●

Global

Health Programs: Advanced Gates Foundation-funded RSV and malaria monoclonal antibody (“mAb”) programs, with C1-produced

antibodies demonstrating high productivity and functional characteristics comparable to established mammalian-cell reference materials.

Funding is in place to advance these programs, and Dyadic is working toward delivery of C1-produced material to support initiation

of preclinical studies with one or both mAbs, providing an additional opportunity to support potential future clinical and commercial

adoption.

Continued

C1 development with CEPI/Fondazione Biotecnopolo di Siena (“FBS”) to accelerate protein-vaccine antigen development and advancing

NIAID-supported preclinical evaluation of C1-produced malaria antigens.

●

Rapid

Pandemic Response Capabilities: Demonstrated C1’s platform agility by producing, purifying and delivering two Scripps-designed

Bundibugyo ebolavirus (“BDBV”) antigens to Scripps Research and FBS in approximately 15 days from plasmid to purified

protein. The antigens are undergoing further characterization and may support future preclinical evaluation, subject to program priorities,

additional evaluation and available funding.

●

Government,

Academic & Industry Adoption: Continued monoclonal antibody development with the Israel Institute for Biological Research

(“IIBR”) and expanded access to C1 strains, processes and development capabilities for academic and industry partners

evaluating next-generation vaccines and therapeutics. Dyadic is also pursuing several potential monoclonal antibody programs through

the European Vaccines Hub/FBS ecosystem, as well as opportunities with prospective first-time C1 collaborators.

Financial

Highlights

Cash

Position: As of June 30, 2026, cash, cash equivalents, restricted cash, and the carrying value of investment-grade securities, including

accrued interest, were $4,794,798 compared to $8,587,289 as of December 31, 2025.

Revenue:

Total revenue for the three months ended June 30, 2026 was $961,138, representing a decrease of $5,492 or 0.6% compared to $966,630 for

the three months ended June 30, 2025. The slight decrease was driven by a $89,563 decrease in research and development revenue resulting

from the reduction in the numbers and size of collaboration activities, and the absence of a $250,000 milestone revenue recorded in 2025,

partially offset by a $334,071 increase in grant revenue from activities under the CEPI and Gates Foundation grants.

Cost

of Revenue: Total cost of revenue for the three months period ended June 30, 2026 was $984,165, representing an increase of $370,574

or 60.4% compared to $613,591 for the three months ended June 30, 2025. The increase was due to a $395,709 increase in cost of grant

revenue from activities under the CEPI and Gates Foundation grants, partially offset by a $25,135 decrease in the cost of research and

development revenue.

R&D

Expenses: Research and development expenses for the three months ended June 30, 2026, were $332,621, a decrease of $296,758 or 47.2%

compared to $629,379 for the same period in 2025. The decrease was due to reduction in the number of active internal research initiatives.

G&A

Expenses: General and administrative expenses for the three months ended June 30, 2026, were $1,689,863, an increase of $253,233

or 17.6%, compared to $1,436,630 for the same period in 2025. The increase was due to higher rebranding and business development expenses

of $322,638, increased legal and accounting expenses of $115,836, and other expenses of $43,639, partially offset by a decrease in share-based

compensation expenses of $196,408 and incentives of $32,472.

Loss

from Operations: Loss from operations for the three months ended June 30, 2026 was $2,054,204, an increase of $325,136 or 18.8%,

compared to $1,729,068 for the same period in 2025. The increase was largely attributable to higher total cost of revenue of $370,574

and higher general and administrative expenses of $253,233, partially offset by lower research and development expenses of $296,758.

Net

Loss: Net loss for the three months ended June 30, 2026, was $2,123,884 or $(0.06) per share, compared to $1,793,774 or $(0.06) per

share for the same period a year ago.

Conference

Call Information

Date:

Wednesday, August 12, 2026

Time:

5:00 p.m. Eastern Time

Dial-in

numbers: Toll Free: +1-877-407-9219 / +1 412-652-1274

Conference

ID:13761129

Webcast

Link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=b9s8dhjS

archive of the webcast will be available within 24 hours after completion of the live event and will be accessible on the Investor Relations

section of the Company’s website at www.dyadic.com. To access the replay of the webcast, please follow the webcast link above.

About

Dyadic Applied BioSolutions

Dyadic

Applied BioSolutions is a global biotechnology company that uses its proprietary microbial platforms to produce recombinant proteins

that are sold or licensed to partners across the life sciences, food and nutrition, and bio-industrial markets. These high-quality proteins

are designed to enable customers to develop more efficient, scalable, and sustainable products. Dyadic’s Dapibus™ and C1

expression systems support flexible, cost-effective manufacturing, and are the foundation of a growing portfolio of commercial and partnered

programs.

For

more information, please visit http://www.dyadic.com.

Safe

Harbor Regarding Forward-Looking Statements

This

press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange

Act, including those regarding Dyadic International’s expectations, intentions, strategies, and beliefs pertaining to future events

or future financial performance, such as the success of our clinical trial and interest in our protein production platforms, our research

projects and third-party collaborations, as well as the availability of necessary funding. Forward-looking statements generally can be

identified by use of the words “expect,” “should,” intend,” anticipate,” “will,” “project,”

“may,” “might,” “potential,” or “continue” or other similar terms or variations of them.

Forward-looking statements involve many risks, uncertainties or other factors beyond Dyadic’s control. These factors include, but

are not limited to, the following: (i) our history of net losses, and management’s related conclusion that there is substantial

doubt about our ability to continue as a going concern for the 12 months following June 30, 2026; (ii) market and regulatory

acceptance of our microbial protein production platforms and other technologies; (iii) failure to commercialize our microbial protein

production platforms or our other technologies; (iv) competition, including from alternative technologies; (v) the results of nonclinical

studies and clinical trials; (vi) our capital needs and the dilutive impact of a capital raise to mitigate our going-concern

risk; (vii) changes in global economic and financial conditions; (viii) our reliance on information technology; (ix)

our dependence on third parties; (x) government regulations and environmental, social and governance issues; (xi) intellectual

property risks; and (xii) our ability to comply with the listing standards of the Nasdaq Stock Market LLC. For a more complete description

of the risks that could cause our actual results to differ from our current expectations, please see the section entitled “Risk

Factors” in Dyadic’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may

be updated from time to time in Dyadic’s periodic filings with the SEC, which are accessible on the SEC’s website and at

www.dyadic.com. All forward-looking statements speak only as of the date made, and except as required by applicable law, Dyadic assumes

no obligation to publicly update any such forward-looking statements for any reason after the date of this press release to conform these

statements to actual results or to changes in our expectations.

Contact:

Dyadic

International, Inc.

Ping

Rawson

Chief

Financial Officer

Phone:

(561) 743-8333

Email:

ir@dyadic.com

DYADIC

INTERNATIONAL, INC. AND SUBSIDIARIES

CONSOLIDATED

STATEMENTS OF OPERATIONS

Three months ended June 30,

Six months ended June 30,

2026

2025

2026

2025

Revenue:

Research and development revenue

$ 123,886

$ 213,449

$ 527,476

$ 396,549

Grant revenue

837,252

503,181

1,324,618

713,653

License and milestone revenue

—

250,000

220,000

250,000

Total revenue

961,138

966,630

2,072,094

1,360,202

Costs and expenses:

Costs of research and development revenue

123,322

148,457

463,479

274,937

Costs of grant revenue

860,843

465,134

1,312,526

636,312

Research and development

332,621

629,379

808,690

1,124,358

General and administrative

1,689,863

1,436,630

3,445,194

3,032,968

Foreign currency exchange (gain) loss

8,693

16,098

(898 )

23,170

Total costs and expenses

3,015,342

2,695,698

6,028,991

5,091,745

Loss from operations

(2,054,204 )

(1,729,068 )

(3,956,897 )

(3,731,543 )

Other income (expense):

Interest income

39,705

49,127

96,896

137,585

Interest expense

(64,479 )

(89,456 )

(128,821 )

(178,699 )

Interest expense - related party

(44,906 )

(24,377 )

(89,745 )

(48,696 )

Total other income (expense), net

(69,680 )

(64,706 )

(121,670 )

(89,810 )

Net loss

$ (2,123,884 )

$ (1,793,774 )

$ (4,078,567 )

$ (3,821,353 )

Basic and diluted net loss per common share

$ (0.06 )

$ (0.11 )

$ (0.13 )

Basic and diluted weighted-average common shares outstanding

36,438,703

30,102,324

36,418,462

30,071,285

See

Notes to Consolidated Financial Statements in Item 1 of Dyadic’s Quarterly Report on Form 10-Q filed with the Securities and Exchange

Commission on August 12, 2026.

DYADIC

INTERNATIONAL, INC. AND SUBSIDIARIES

CONSOLIDATED

BALANCE SHEETS

June 30, 2026

December 31, 2025

(Unaudited)

(Audited)

Assets

Current assets:

Cash and cash equivalents

$ 1,425,364

$ 4,622,331

Short-term investment securities

1,688,355

2,698,661

Restricted cash

1,555,649

1,231,168

Interest receivable

16,014

35,129

Accounts receivable

1,302,439

1,090,297

Prepaid expenses and other current assets

418,943

219,067

Total current assets

6,406,764

9,896,653

Non-current assets:

Long-term investment securities

109,416

—

Operating lease right-of-use asset, net

9,851

38,535

Other assets

10,500

10,537

Total assets

$ 6,536,531

$ 9,945,725

Liabilities and stockholders’ equity

Current liabilities:

Accounts payable

$ 816,059

$ 852,024

Accrued expenses

1,395,680

967,974

Deferred research and development obligations

1,564,172

1,730,852

Operating lease liability

5,054

34,621

Accrued interest

60,000

Accrued interest- related party

41,800

Total current liabilities

3,882,765

3,687,271

Non-current liabilities:

Convertible notes, net of issuance costs

2,971,125

2,962,304

Convertible notes, net of issuance costs - related party

2,069,885

2,063,740

Total liabilities

8,923,775

8,713,315

Commitments and contingencies (Note 5)

Stockholders’ equity:

Preferred stock, $.0001 par value:

Authorized shares - 5,000,000; none issued and outstanding

—

Common stock, $.001 par value:

Authorized shares - 100,000,000; issued shares - 48,692,205 and 48,441,300, outstanding shares - 36,438,703 and 36,187,798 as of June 30, 2026, and December 31, 2025, respectively

48,693

48,442

Additional paid-in capital

114,023,653

113,564,991

Treasury stock shares held at cost - $12,253,502

(18,929,915 )

Accumulated deficit

(97,529,675 )

(93,451,108 )

Total stockholders’ (deficit) equity

(2,387,244 )

1,232,410

Total liabilities and stockholders’ equity

$ 6,536,531

$ 9,945,725

See

Notes to Consolidated Financial Statements in Item 1 of Dyadic’s Quarterly Report on Form 10-Q filed with the Securities and Exchange

Commission on August 12, 2026.

GRAPHIC

Filename: logo_001.jpg · Sequence: 3

Binary file (14327 bytes)

Download logo_001.jpg

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 4

Binary file (6325 bytes)

Download ex99-1_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.1

Cover

Aug. 12, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 12, 2026

Entity File Number

001-32513

Entity Registrant Name

Dyadic

International, Inc.

Entity Central Index Key

0001213809

Entity Tax Identification Number

45-0486747

Entity Incorporation, State or Country Code

Entity Address, Address Line One

1044

North U.S. Highway One

Entity Address, Address Line Two

Suite 201

Entity Address, City or Town

Jupiter

Entity Address, State or Province

Entity Address, Postal Zip Code

33477

City Area Code

(561)

Local Phone Number

743-8333

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, par value $0.001 per share

Trading Symbol

DYAI

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration